Engitix
London
About Engitix
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $85.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: engitix.com
- Phone: +44 (0)204 530 7654
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/engitix-50681 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.